Genome Editing

Tools like CRISPR/Cas (protein-RNA guided) and TALENs (protein guided) make specific changes to the DNA of plants, animals, and microorganisms typically without incorporating foreign DNA

LUX TAKE:

Genome editing is the future of agriculture, food ingredients, and medical therapeutics, but CRISPR/cas9 is not the be-all, end-all genome editing approach. Look for alternative cas proteins and non-CRISPR-based tools as legitimate, affordable, widely applicable options rather than focusing solely on CRISPR/Cas9. For human therapeutics progress, focus on scientific and clinical trial results ...

Lux Take last updated on July 08, 2020
Data last updated on January 18, 2023

What's New

Lux Research analysts and the Lux Intelligence Engine have added the following recent genome editing developments.

News Commentaries

The CIA’s venture arm, In-Q-Tel, invests in Colossal Biosciences (October 7, 2022)

Lessafre acquires Recombia Biosciences to enhance synbio presence (September 23, 2022)

New Lux Content

Wayfinder Biosciences (December 2, 2022)

Beyond Made in China 2025: China's Move up the Global Innovation Value Chain (September 6, 2022)

Related companies	Cibus, Calyxt, Benson Hill Biosystems, Computomics, Precision Biosciences, The Samuel Roberts Noble Foundation, AgGenetics, Hudson River Biotechnology, Caribou Biosciences, Inscripta, PLANTeDIT, Tropic Biosciences, Sundew

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Interested in Learning More?

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978